Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marija Jovanović, Katarina Vučićević & Branislava Miljković. (2020) Understanding variability in the pharmacokinetics of atypical antipsychotics – focus on clozapine, olanzapine and aripiprazole population models. Drug Metabolism Reviews 52:1, pages 1-18.
Read now
Read now
Articles from other publishers (32)
Fei Wang, Zhuo-hui Huang, Christine Migliorini, Shi-Bin Wang, Zi-Lang Chen, Qian-Wen Wang, Xiao-Yan He, Carol Harvey & Cai-Lan Hou. (2023) Two-year cohort-up study of clozapine prescription in Chinese patients with schizophrenia treated in rural primary care. Asian Journal of Psychiatry 81, pages 103434.
Crossref
Crossref
Michaela Mayerová & Libor Ustohal. (2022) Some of the less frequent side effects of antipsychotics. Psychiatrie pro praxi 23:3, pages 144-149.
Crossref
Crossref
Aurélie Lereclus, Théo Korchia, Camille Riff, Frédéric Dayan, Olivier Blin, Sylvain Benito & Romain Guilhaumou. (2022) Towards Precision Dosing of Clozapine in Schizophrenia: External Evaluation of Population Pharmacokinetic Models and Bayesian Forecasting. Therapeutic Drug Monitoring 44:5, pages 674-682.
Crossref
Crossref
Estela Sangüesa, Christine Cirujeda, Julia Concha, Pedro Pablo Padilla, Cristina Belén García & María Pilar Ribate. (2022) Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions?. Chemico-Biological Interactions 364, pages 110042.
Crossref
Crossref
Estela Sangüesa, Christine Cirujeda, Julia Concha, Pedro Pablo Padilla, Cristina Belén García & María Pilar Ribate. (2022) Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine. Personalized Medicine 19:3, pages 181-192.
Crossref
Crossref
Kohei Kitagawa, Ryuhei So, Nobuyuki Nomura, Masaru Tsukahara, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Robert Bies, Thomas Straubinger, Christopher Banker, Yuya Mizuno, Masaru Mimura & Hiroyoshi Takeuchi. (2022) Clozapine Once-Daily Versus Divided Dosing Regimen. Journal of Clinical Psychopharmacology 42:2, pages 163-168.
Crossref
Crossref
Anna Ohlis, Alma Sörberg Wallin, Anna Sarafis, Hugo Sjöqvist, James H. MacCabe, Johan Ahlen & Christina Dalman. (2021) Clozapine treatment and risk of severe COVID‐19 infection. Acta Psychiatrica Scandinavica 145:1, pages 79-85.
Crossref
Crossref
Defaru Desalegn, Zakir Abdu & Mohammedamin Hajure. (2021) Prevalence of tobacco dependence and associated factors among patients with schizophrenia attending their treatments at southwest Ethiopia; hospital-based cross-sectional study. PLOS ONE 16:12, pages e0261154.
Crossref
Crossref
Masaru Nakamura & Takahiko Nagamine. (2021) Metabolic Effects of Clozapine Administration Based on Sex Differences and the Relationships Between Dosage and Prolactin Levels: An Observational Study. Clinical Neuropharmacology 44:6, pages 205-209.
Crossref
Crossref
Helmi Ammar, Zohra Chadli, Ahmed Mhalla, Sabria Khouadja, Ibtissem Hannachi, Mohammed Alshaikheid, Ahlem Slama, Nadia Ben Fredj, Najeh Ben Fadhel, Haifa Ben Romdhane, Amel Chaabane, Naceur A. Boughattas, Lotfi Gaha, Lazhar Zarrouk & Karim Aouam. (2021) Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. The Pharmacogenomics Journal 21:5, pages 551-558.
Crossref
Crossref
Gul KaracetinCagatay ErmisEsra Bulanik Koc & Yesim Saglam. (2021) Investigating Predictors of Clozapine Response in Adolescents with Schizophrenia and Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology 31:7, pages 504-510.
Crossref
Crossref
Mariko Tsukiji, Tsuyoshi Sasaki, Yusuke Nakata, Kiyomitsu Ota, Tsutomu Aoki, Koichiro Hara, Takashi Mamada, Jun Nakane, Masanobu Kogure, Ryota Seki, Keita Idemoto, Tasuku Hashimoto, Hiraki Koishikawa, Toshihiro Moriyama, Takaaki Suzuki, Nobuhisa Kanahara, Itsuko Ishii, Masaomi Iyo & Tomihisa Niitsu. (2021) Risk factors for early-phase clozapine discontinuation: A nested case-control study. Asian Journal of Psychiatry 62, pages 102745.
Crossref
Crossref
Maxim Kuzin, Ekkehard Haen, Christoph Hiemke, Benjamin Bochon, Karolina Bochon, Gerhard Gründer, Michael Paulzen & Georgios Schoretsanitis. (2021) Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. Journal of Psychopharmacology 35:3, pages 273-278.
Crossref
Crossref
Salma Rehimini, Karin G. Goddard & Howard C. Margolese. (2021) Exceptionally High Clozapine-Associated Eosinophilia. Journal of Clinical Psychopharmacology 41:2, pages 216-218.
Crossref
Crossref
Francesca Martini, Marco Spangaro, Mariachiara Buonocore, Margherita Bechi, Federica Cocchi, Carmelo Guglielmino, Laura Bianchi, Jacopo Sapienza, Giulia Agostoni, Antonella Mastromatteo, Marta Bosia & Roberto Cavallaro. (2021) Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex. Psychiatry Research 297, pages 113698.
Crossref
Crossref
Madeleine S. A. Tan, Faraz Honarparvar, James R. Falconer, Harendra S. Parekh, Preeti Pandey & Dan J. Siskind. (2021) A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology 238:3, pages 615-637.
Crossref
Crossref
Banu Manickam Rajalu, Deepak Jayarajan, Krishna Prasad Muliyala, Priyamvada Sharma, Sailaxmi Gandhi, Prabhat Kumar Chand, Jagadisha Thirthalli & Pratima Murthy. (2021) Non-pharmacological interventions for smoking in persons with schizophrenia spectrum disorders – A systematic review. Asian Journal of Psychiatry 56, pages 102530.
Crossref
Crossref
Graham Blackman, Jenny E.L. Lisshammar, Rayyan Zafar, Thomas A. Pollak, Megan Pritchard, Alexis E. Cullen, Jonathan Rogers, Ben Carter, Kira Griffiths, Matthew Nour, Anthony S. David, Philip McGuire, Robert Stewart & James MacCabe. (2021) Clozapine Response in Schizophrenia and Hematological Changes. Journal of Clinical Psychopharmacology 41:1, pages 19-24.
Crossref
Crossref
Georgios Schoretsanitis, Ekkehard Haen, Andreas Conca, Daria Piacentino, Florian Ridders, Christoph Hiemke, Gerhard Gründer & Michael Paulzen. (2020) Lack of Smoking Effects on Pharmacokinetics of Oral
Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring
Sample. Pharmacopsychiatry 54:01, pages 31-35.
Crossref
Crossref
E. Wagner, L. McMahon, P. Falkai, A. Hasan & D. Siskind. (2020) Impact of smoking behavior on clozapine blood levels – a systematic review and meta‐analysis. Acta Psychiatrica Scandinavica 142:6, pages 456-466.
Crossref
Crossref
Arthur S. Nguyen, Rebecca Grossman-Kahn & Lora Wichser. (2020) Anticipatory Clozapine Dosing After Discharge From Inpatient Treatment for the Patient With Comorbid Schizophrenia and Tobacco Use. Journal of Clinical Psychopharmacology 40:6, pages 618-619.
Crossref
Crossref
Rajendra P. Shukla, Crystal Rapier, Matthew Glassman, Fang Liu, Deanna L. Kelly & Hadar Ben-Yoav. (2020) An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients. Electrochemistry Communications 120, pages 106850.
Crossref
Crossref
Ching-Hua Lin, Hung-Yu Chan, Chun-Chi Hsu & Feng-Chua Chen. (2020) Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006–2017. Scientific Reports 10:1.
Crossref
Crossref
Tiffany Buckley, Christopher Kitchen, Gopal Vyas, Nathan A. Siegfried, Eshetu Tefera, Shuo Chen, Bethany A. DiPaula & Deanna L. Kelly. (2020) Comparison of Novel Immunoassay With Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for Therapeutic Drug Monitoring of Clozapine. Therapeutic Drug Monitoring 42:5, pages 771-777.
Crossref
Crossref
Albert T. Higgins-Chen, Marco P. Boks, Christiaan H. Vinkers, René S. Kahn & Morgan E. Levine. (2020) Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects. Biological Psychiatry 88:3, pages 224-235.
Crossref
Crossref
Julia Kim, Eric Plitman, Yusuke Iwata, Shinichiro Nakajima, Wanna Mar, Raihaan Patel, Sofia Chavez, Jun Ku Chung, Fernando Caravaggio, M. Mallar Chakravarty, Gary Remington, Philip Gerretsen & Ariel Graff-Guerrero. (2020) Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 99, pages 109839.
Crossref
Crossref
Ivana Tašková & Kateřina Langmaierová. (2020) Psychiatric patient in community pharmacy. Praktické lékárenství 16:1, pages 17-20.
Crossref
Crossref
Michael D. Coleman. 2020. Human Drug Metabolism. Human Drug Metabolism
331
446
.
Orwa Albitar, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim & Siti Maisharah Sheikh Ghadzi. (2020) Population Pharmacokinetics of Clozapine: A Systematic Review. BioMed Research International 2020, pages 1-10.
Crossref
Crossref
William Clarke & Mark A. Marzinke. 2020. Contemporary Practice in Clinical Chemistry. Contemporary Practice in Clinical Chemistry
895
904
.
Sandeep Grover & Swapnajeet Sahoo. (2019) Treatment of Clozapine Nonresponders. Current Treatment Options in Psychiatry 6:1, pages 32-63.
Crossref
Crossref
Je-Yeon YunJung Suk LeeShi Hyun KangBeomwoo NamSeung Jae LeeSeung-Hwan LeeJoonho ChoiChan-Hyung KimYoung-Chul Chung. (2019) Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia. Korean Journal of Schizophrenia Research 22:2, pages 21.
Crossref
Crossref